Can Urinary Complement Proteins Stratify Patients to Therapeutic Complement Inhibitors?
作者信息
Medjeral-Thomas Nicholas R
机构信息
Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.
出版信息
Kidney Int Rep. 2022 Mar 28;7(5):939-941. doi: 10.1016/j.ekir.2022.03.024. eCollection 2022 May.
Abstract
摘要
相似文献
1
Can Urinary Complement Proteins Stratify Patients to Therapeutic Complement Inhibitors?
Kidney Int Rep. 2022 Mar 28;7(5):939-941. doi: 10.1016/j.ekir.2022.03.024. eCollection 2022 May.
2
High levels of urinary complement proteins are associated with chronic renal damage and proximal tubule dysfunction in immunoglobulin A nephropathy.
Nephrology (Carlton). 2019 Jul;24(7):703-710. doi: 10.1111/nep.13477. Epub 2019 Apr 23.
3
Urinary complement proteins and risk of end-stage renal disease: quantitative urinary proteomics in patients with type 2 diabetes and biopsy-proven diabetic nephropathy.
J Endocrinol Invest. 2021 Dec;44(12):2709-2723. doi: 10.1007/s40618-021-01596-3. Epub 2021 May 27.
4
Complement activation profile of patients with primary focal segmental glomerulosclerosis.
PLoS One. 2020 Jun 22;15(6):e0234934. doi: 10.1371/journal.pone.0234934. eCollection 2020.
5
Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.
BMC Nephrol. 2011 Nov 23;12:64. doi: 10.1186/1471-2369-12-64.
6
Complement activation products in the circulation and urine of primary membranous nephropathy.
BMC Nephrol. 2019 Aug 9;20(1):313. doi: 10.1186/s12882-019-1509-5.
7
Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy.
Nephron Clin Pract. 2004;97(4):c147-53. doi: 10.1159/000079174.
8
Molecular Mapping of Urinary Complement Peptides in Kidney Diseases.
Proteomes. 2021 Dec 13;9(4):49. doi: 10.3390/proteomes9040049.
9
Significance of urinary complement components in various glomerular diseases.
Thromb Res. 1990 Feb 15;57(4):625-37. doi: 10.1016/0049-3848(90)90080-v.
10
Complement Activation Is Associated With Crescents in IgA Nephropathy.
Front Immunol. 2021 Sep 14;12:676919. doi: 10.3389/fimmu.2021.676919. eCollection 2021.
引用本文的文献
1
Targeting complement in IgA nephropathy.
Clin Kidney J. 2023 Dec 4;16(Suppl 2):ii28-ii39. doi: 10.1093/ckj/sfad198. eCollection 2023 Dec.
本文引用的文献
1
Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis.
Kidney Int Rep. 2022 Feb 14;7(5):1027-1036. doi: 10.1016/j.ekir.2022.02.002. eCollection 2022 May.
2
Avacopan for the Treatment of ANCA-Associated Vasculitis.
N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386.
3
The Complement System in Lupus Nephritis.
Semin Nephrol. 2015 Sep;35(5):444-54. doi: 10.1016/j.semnephrol.2015.08.006.
4
Complement System Part I - Molecular Mechanisms of Activation and Regulation.
Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015.
5
Current Understanding of the Role of Complement in IgA Nephropathy.
J Am Soc Nephrol. 2015 Jul;26(7):1503-12. doi: 10.1681/ASN.2014101000. Epub 2015 Feb 18.
6
C3 glomerulopathy: consensus report.
Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.
7
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
8
The molecular biology of thrombotic microangiopathy.
Kidney Int. 2006 Jul;70(1):16-23. doi: 10.1038/sj.ki.5001535. Epub 2006 May 31.
9
Complement activation products in the urine from proteinuric patients.
J Am Soc Nephrol. 2000 Apr;11(4):700-707. doi: 10.1681/ASN.V114700.
Zotero 插件